ClinicalTrials.gg
RecruitingNCT06727253Updated Oct 15, 2026

Glycan Supplementation on a Human Model of Crohn's Disease Initiation and Progression

An interventional study of Glycan in Crohn Disease (CD), sponsored by GLSMED Learning Health S.A.. Recruiting at 1 site in Portugal. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by GLSMED Learning Health S.A. · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Crohn Disease with a site in Portugal — 16 open to participants now, 23 under way, 15 of them phase 3. Crohn Disease · Portugal.

Planned enrollment
44th of 45
30 · median 500
Started
2025
with 5 others
No phase
2 of 53
1 open now
Primary completion
2028-06
later than 9 of 22 live
Registered
48th of 53
by date
Lead sponsor
3 of 53
GLSMED Learning Health S.A.

Among the 53 studies in Crohn Disease with a site in Portugal, this one is the 44th largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2025, is one of 2 with no phase, reaches primary completion later than 9 of the 22 other live ones, and was the 48th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

16 of the 53 studies in Crohn Disease with a site in Portugal are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Crohn Disease with a site in Portugal, or all of them as a file.
02

Study summary

The overall aim of this proof-of-concept trial is to investigate the effect of an orally administered glycan on the modulation of the dysregulation of host-microbiome interactions and its effect on the mucosal immune response. Post-operative Crohn's Disease patients will be used as a representative model to mimic the immunopathogenic pathway of health-to-disease transition. Changes in gut glycocalyx seem to be a primary event involved in the disruption of the interaction between the microbiota and the host immune system. Thus, this study aims to assess the effect of the modulation of the glycome on the microbial and immunological changes that contribute to disease development.

Read the detailed description

Inclusion Criteria

  • Male or female patients between 18 and 75 years old able to provide oral and written informed consent for participation in the study
  • Confirmed diagnosis of ileal or ileocolonic CD
  • Submitted to ICR or ileal resection for removing the diseased segment of the bowel.

Exclusion Criteria

  • Diagnosis of indeterminate colitis, ulcerative colitis or microscopic colitis, including collagenous colitis or lymphocytic colitis
  • Patients receiving antibiotics, aminosalicylates, thiopurines, methotrexate, biologics or small molecules after surgery for postoperative recurrence
  • Patients with previous ICR or ileal resection due to CD, unless the treating physician does not intend to start other prophylactic therapy apart from the glycan supplement within the first 6 months following surgery
  • Pregnant or lactating women
  • Documented allergy to shellfish, glycans or glycans derivatives
  • History of dysplasia on colonic biopsy
  • Presence of, or history of cancer, except for skin cancer
  • History of poorly controlled type 1 or type 2 diabetes, defined as HbA1c greater than 8% or recurrent episodes of hyperglycaemic crisis such as diabetic ketoacidosis or hyperglycaemic hyperosmolar state
  • Patients with known bleeding disorders, such as hemophilia or thrombocytopenia, or those receiving anticoagulation therapy, such as warfarin or direct oral anticoagulants
  • Any physical or mental condition which would interfere with the ability to provide written and oral free informed consent or limit the study participation, collection of data, or study completion as determined by the Investigator
  • Unwillingness or inability to follow the procedures outlined in the protocol.
03

Conditions studied

  • Crohn Disease (CD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 75 years old (inclusive) able to provide oral and written for participation in the study
  • Confirmed diagnosis of ileal or ileocolonic CD (according to ECCO guidelines)
  • Patients submitted to ileal and ileocecal resection for removing the diseased segment of the bowel.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of indeterminate colitis, ulcerative colitis or microscopic colitis (collagenous colitis or lymphocytic colitis)
  • Patients receiving antibiotics, aminosalicylates, thiopurines, methotrexate, biologics or small molecules after surgery for postoperative recurrence
  • Patients with previous ICR or ileal resection due to CD, unless the treating physician does not intend to start other prophylactic therapy apart from the glycan supplement within the first 6 months following surgery
  • Pregnant or lactating women
  • Documented allergy to shellfish, glycans or glycans derivatives
  • History of dysplasia on colonic
  • Presence of, or history of cancer, except for skin cancer
  • History of poorly controlled type 1 or type 2 diabetes (>8% or recurrent episodes of hyperglycaemic crisis such as diabetic ketoacidosis or hyperglycaemic hyperosmolar state)
  • Patients with known bleeding disorders (e.g. haemophilia or thrombocytopenia) or anticoagulation therapy (e.g. warfarin or direct oral anticoagulants)
  • Any physical or mental condition which would interfere with the ability to provide written and oral free or limit the study participation, collection of data, or study completion as determined by the Investigator
  • Unwillingness or inability to follow the procedures outlined in the protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Single Arm, Dietary Supplement: Glycan

    Dietary Supplement: Glycan

Interventions

  • Dietary supplementGlycan

    The post-operative CD patients will receive an orally administered glycan.

06

What researchers measure

Primary outcomes

  1. The effect of the modulation of the glycome on the microbial changes that contribute to disease development

    Time frame: From enrolment until 6 months following surgery

  2. The effect of the modulation of the glycome on the immunological changes that contribute to disease development

    Time frame: From enrolment until 6 months following surgery

Secondary outcomes

  1. The immunomodulatory effect of glycans on endoscopic recurrence

    Time frame: From enrolment until 6 months following surgery

  2. The immunomodulatory effect of glycans on clinical recurrence

    Time frame: From enrolment until 6 months following surgery

  3. The immunomodulatory effect of glycans on histological recurrence

    Time frame: From enrolment until 6 months following surgery

  4. The immunomodulatory effect of glycans on systemic inflammatory biomarkers pre-surgery

    Time frame: From enrolment until 6 months following surgery

  5. The immunomodulatory effect of glycans on systemic inflammatory biomarkers post-surgery

    Time frame: From enrolment until 6 months following surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.

Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 36 months is below that.

Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Dec 10, 2024
StartActual
May 26, 2025
Primary completionEst.
Jun 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06727253
Lead sponsor
GLSMED Learning Health S.A.
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
May 26, 2025
Primary completion
Jun 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Catarina IM Barbosa, PhD
Contact
catarina.moreira.barbosa@luzsaude.pt
+351217104544

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion